Compare iShares Core MSCI Emerging Markets ETF (IEMG) vs Nuwellis Inc (NUWE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI Emerging Markets ETF vs Nuwellis Inc — how do they compare? iShares Core MSCI Emerging Markets ETF trades at $81.15 (market cap $162.00B), while Nuwellis Inc trades at $0.68 (market cap $2.20M). The key difference: iShares Core MSCI Emerging Markets ETF is far larger — about 73636.4× Nuwellis Inc's market cap, and iShares Core MSCI Emerging Markets ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Core MSCI Emerging Markets ETF for 57 Days and Nuwellis Inc for 26 Days on average.
| IEMG | NUWE | |
|---|---|---|
Market Cap | $162.00B | $2.20M |
Volume | 13,446,151 | 121,544 |
Sector | Broad Market / Factor | Health |
52-Week High | $86.00 | $146.65 |
52-Week Low | $64.22 | $0.68 |
Typical Hold Time | 57 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEMG trades at $81.14, down 1.1% with a bearish technical signal from moving averages. The ETF's emerging markets focus has delivered strong recent performance, with articles highlighting 35% one-year returns and record asset inflows. Technical indicators show neutral oscillators but bearish momentum, with key support at $79 and resistance at $82.
Emerging markets exposure offers growth potential amid dollar weakness, though higher volatility and expense ratios compared to developed market ETFs present risks. The fund's 39% technology weighting and outperformance versus peers like SCHE and VWO provide differentiation, but concentration risks and market sensitivity require careful monitoring.
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI Emerging Markets ETF
IEMG tracks the MSCI Emerging Markets Investable Market Index, providing broad exposure to large, mid, and small-cap stocks across over 20 emerging market countries. It is designed as a low-cost core holding for investors seeking diversified growth from economies outside of developed markets.
Read more on IEMG →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
